drugset / Trial / NCT03497429
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelOther
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Niraparib in Japanese participants with advanced solid tumors.
Timeline
- Start
- 2018-04-05
- Primary completion
- 2020-02-10
- Completion
- 2020-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |